The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Timeframe: Up to approximately 52 weeks
Percentage of Participants With Adjudicated Major Adverse Cardiovascular Event
Timeframe: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations
Timeframe: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders
Timeframe: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Hypoglycemia
Timeframe: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis
Timeframe: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Muscular Disorder
Timeframe: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Neurocognitive Disorder
Timeframe: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: New Onset or Worsening Diabetes Mellitus
Timeframe: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Renal Disorder
Timeframe: Up to approximately 52 weeks
Change From Baseline to Week 52 in Uric Acid (Urate) Level
Timeframe: Baseline and Week 52
Change From Baseline to Week 52 in Creatinine Level
Timeframe: Baseline and Week 52
Change From Baseline to Week 52 in Hemoglobin Level
Timeframe: Baseline and Week 52